SCHEMBL5134793

SCHEMBL5134793

O=C(c1cc(C(F)(F)F)ccc1-c1ccccc1)N(Cc1ccccc1)Cc1ccc2c(c1)OCO2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
HPGD P15428 4/20 0.55
MAPT P10636 2/20 0.55
NPSR1 Q6W5P4 2/20 0.52
UBE2M P61081 1/20 0.46
DCUN1D1 Q96GG9 1/20 0.46
TSHR P16473 4/20 0.45
TDP1 Q9NUW8 1/20 0.45
USP2 O75604 2/20 0.44
TAS2R14 Q9NYV8 1/20 0.44
MAPK1 P28482 2/20 0.44
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
HTR5A P47898 1/20 0.43
PTPN1 P18031 1/20 0.43
KMT2A Q03164 1/20 0.43
KDM4E B2RXH2 1/20 0.43
POLB P06746 1/20 0.43
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4766559 0.90 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2HPGDMAPTNPSR1
SCHEMBL5134630 0.85 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2HPGDMAPTNPSR1
SCHEMBL5136876 0.83 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2HPGDMAPTNPSR1
SCHEMBL4769015 0.80 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2HPGDMAPTNPSR1
SCHEMBL14099478 0.76 ALDH1A1 (0.64) ALDH1A1SMN1; SMN2HPGDMAPTNPSR1
SCHEMBL5359612 0.74 TACR1 (0.57) ALDH1A1TSHRKMT2AKDM4EGPBAR1
SCHEMBL14586262 0.72 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2HPGDMAPTNPSR1
SCHEMBL5358691 0.71 MAPT (0.42) ALDH1A1HPGDMAPTNPSR1TSHR
SCHEMBL5134546 0.71 ALDH1A1 (0.45) ALDH1A1HPGDMAPTNPSR1UBE2M
SCHEMBL17072329 0.71 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2HPGDMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7271270-B2 High affinity small molecule C5a receptor modulators NEUROGEN CORPORATION (US) 2007-09-18 US disclosed
US-6884815-B1 High affinity small molecule C5a receptor modulators NEUROGEN CORPORATION (US) 2005-04-26 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed